{"gene":"DLL3","run_date":"2026-04-28T17:46:02","timeline":{"discoveries":[{"year":1997,"finding":"Mouse Dll3, a divergent Delta homologue, can activate the Notch receptor and inhibit primary neurogenesis when ectopically expressed in Xenopus, demonstrating it is a functional Delta homologue capable of activating Notch signaling.","method":"Ectopic expression in Xenopus embryos (gain-of-function assay)","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 2 — functional in vivo assay in Xenopus, single lab, single method","pmids":["9272948"],"is_preprint":false},{"year":1998,"finding":"Loss-of-function mutation in Dll3 (pudgy mouse) disrupts proper formation of morphological borders in early somite formation and rostral-caudal compartment boundaries within somites, establishing Dll3 as required for initiation of patterning of vertebrate paraxial mesoderm via a Notch-signalling pathway.","method":"Positional cloning, complementation testing, histological and molecular marker analyses in pudgy (pu) mouse mutants","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 — positional cloning plus in vivo loss-of-function with defined molecular phenotype, foundational paper with 237 citations","pmids":["9662403"],"is_preprint":false},{"year":2000,"finding":"Mutations in human DLL3, including truncating mutations in conserved extracellular domains and a missense mutation in the fifth EGF repeat, cause autosomal recessive spondylocostal dysostosis, establishing that the EGF-like repeat domain is functionally critical.","method":"Mutational analysis (sequencing) of DLL3 in spondylocostal dysostosis families; functional inference from domain conservation","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — human genetics with multiple families and domain-level functional inference, replicated across families, 306 citations","pmids":["10742114"],"is_preprint":false},{"year":2002,"finding":"Loss-of-function mutation in mouse Dll3 (targeted null allele Dll3neo) causes disruption of the segmentation clock in the presomitic mesoderm, evidenced by perturbed oscillatory expression of Lfng, Hes1, Hes5, and Hey1, resulting in delayed and irregular somite formation and loss of anteroposterior somite polarity.","method":"Gene targeting (null allele), expression analysis of cycling genes by in situ hybridization in mutant embryos","journal":"Development","confidence":"High","confidence_rationale":"Tier 1-2 — clean KO with multiple molecular markers of segmentation clock, well-controlled study","pmids":["11923214"],"is_preprint":false},{"year":2003,"finding":"Dll1 and Dll3 operate in feedback loops with Mesp2 for rostrocaudal patterning of somites; genetic epistasis analysis shows Dll1 and Dll3 have non-redundant and potentially counteracting functions in the presomitic mesoderm, with Mesp2 acting downstream of both Notch ligands.","method":"Genetic epistasis analysis using Dll1, Dll3, Mesp2, and Psen1 mutant mice; gene expression analysis in compound mutants","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 — epistasis analysis with multiple compound mutants, clear pathway placement","pmids":["12900443"],"is_preprint":false},{"year":2004,"finding":"The Dll3 pudgy mutation differentially disrupts cycling (Lfng, Hes7) versus stage-specific (Hey3, Mesp2) genes in paraxial mesoderm, suggesting Dll3 participates in more than one oscillatory mechanism during somitogenesis.","method":"Expression analysis of cycling and stage-specific genes in Dll3 pudgy mutant embryos by in situ hybridization","journal":"Genesis","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with multiple molecular readouts, single lab","pmids":["15170697"],"is_preprint":false},{"year":2005,"finding":"DLL3 does not activate Notch signaling (unlike other DSL ligands); it does not bind Notch receptors in trans and Notch1 does not bind DLL3-expressing cells, but DLL3 cell-autonomously suppresses Notch signaling (cis-inhibition), promoting neurogenesis and inhibiting glial differentiation. Together with lunatic fringe, DLL3 modulates Notch signaling levels induced by other DSL ligands.","method":"Multiple Notch activation assays, cell-binding assays (trans-binding), co-culture signaling assays, Xenopus neurogenesis assay, mouse neural progenitor differentiation assay","journal":"Journal of Cell Biology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal assays in one study demonstrating DLL3 as a dedicated Notch cis-inhibitor rather than activator; 233 citations","pmids":["16144902"],"is_preprint":false},{"year":2007,"finding":"Dll3-Notch1 double heterozygous mice exhibit localized segmental vertebral anomalies and craniofacial defects not seen in single heterozygotes, demonstrating a genetic interaction between Dll3 ligand and Notch1 receptor in axial segmentation and craniofacial development.","method":"Compound mutant mouse analysis (double heterozygosity), skeletal phenotyping, microarray gene expression","journal":"Developmental Dynamics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic interaction established by compound heterozygous phenotype, single lab","pmids":["17849441"],"is_preprint":false},{"year":2008,"finding":"The intracellular domain of Dll3 (which contains no lysine) directs endocytosis and recycling via an ubiquitination-independent signal; a Dll1-Dll3 chimera (Dll1 ectodomain + Dll3 transmembrane/intracellular domain) is endocytosed, recycled, and binds Notch1 but cannot induce transendocytosis of the Notch1 extracellular region and therefore cannot activate Notch signaling, indicating that transendocytosis—not merely receptor binding—is required for Notch activation and that the Dll3 intracellular domain specifically lacks this capacity.","method":"Chimeric ligand construction, endocytosis/recycling assays, Notch1 binding assays, transendocytosis assays in cell culture","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution with chimeric molecules plus mechanistic dissection of multiple steps (endocytosis, recycling, binding, transendocytosis), multiple orthogonal methods","pmids":["18676613"],"is_preprint":false},{"year":2009,"finding":"The ubiquitin ligase Huwe1 restrains neural stem cell proliferation and enables neurogenesis by suppressing the N-Myc–DLL3 cascade; loss of Huwe1 in the mouse cortex leads to uncontrolled expansion of neural stem cells associated with upregulation of DLL3, placing DLL3 downstream of N-Myc and upstream of Notch in neural stem cell regulation.","method":"Conditional Huwe1 knockout in mouse brain, loss- and gain-of-function experiments, cortical layering and neurogenesis phenotyping","journal":"Developmental Cell","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined cellular phenotype and pathway placement (Huwe1→N-Myc→DLL3→Notch), replicated with gain-of-function","pmids":["19686682"],"is_preprint":false},{"year":2009,"finding":"Dll3 is required for normal cyclical expression of Nrarp (a Notch/Wnt regulator) in the presomitic mesoderm during somitogenesis; in Dll3 null embryos Nrarp shows static (non-cycling) expression, while Lfng null embryos eventually resume Nrarp cycling, indicating that Dll3 is specifically required for Nrarp oscillation independently of Lfng.","method":"Microdissection of somitic/presomitic mesoderm, gene expression analysis by in situ hybridization in Dll3 null, Lfng null, and Wnt3a null embryos","journal":"Developmental Biology","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function in multiple mutant backgrounds with defined target gene, single lab","pmids":["19268448"],"is_preprint":false},{"year":2009,"finding":"The bHLH transcription factors Ascl1 (Mash1) and Neurog2 form novel DNA-binding complexes (including Ascl1/Ascl1 homodimers and Ascl1/Neurog2 heterodimers) that bind E-boxes in the conserved proximal Dll3 promoter to regulate Dll3 expression in the dorsal neural tube; individual E-boxes function as distinct enhancers or repressors.","method":"Transgenic mouse reporter assays, E-box mutagenesis, in vitro DNA-binding assays, loss-of-function analysis of Ascl1 and Neurog2","journal":"Developmental Biology","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro binding assays combined with transgenic reporter and mutagenesis in vivo, multiple orthogonal methods","pmids":["19389376"],"is_preprint":false},{"year":2015,"finding":"O-fucosylation of DLL3 EGF-like repeats 2 and 5 (at POFUT1 consensus sites) is essential for DLL3 function during somitogenesis in vivo; O-fucosylation-deficient DLL3 can still interact with LFNG, Notch1, and DLL1 and retains cis-inhibitory activity in vitro, but cannot rescue the Dll3 null somitogenesis defect, and DLL3 and LFNG interact physically within the trans-Golgi.","method":"Site-directed mutagenesis of O-fucosylation sites, transgenic rescue experiments in Dll3 null embryos, co-immunoprecipitation of DLL3 and LFNG, in vitro Notch inhibition assays","journal":"PLoS ONE","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis + in vivo rescue + co-IP + in vitro assay, multiple orthogonal methods in single study","pmids":["25856312"],"is_preprint":false},{"year":2019,"finding":"DLL3 promotes migration and invasion of SCLC cells by positively regulating SNAI1 (Snail) expression; DLL3 knockdown reduced migration/invasion and SNAI1 levels, while DLL3 overexpression increased them, and SNAI1 knockdown attenuated DLL3-driven migration/invasion. DLL3 overexpression also promoted subcutaneous tumor growth in mice.","method":"Loss-of-function (siRNA knockdown) and gain-of-function (overexpression) in SCLC cell lines, transwell migration/invasion assay, SNAI1 expression analysis, mouse xenograft model","journal":"Cancer Science","confidence":"Medium","confidence_rationale":"Tier 2 — both KD and OE with defined molecular (SNAI1) and cellular phenotype, in vitro and in vivo","pmids":["30874360"],"is_preprint":false},{"year":2019,"finding":"DLL3 mRNA is stabilized by the RNA-binding protein LIN28B, and both LIN28B and DLL3 are downstream targets of miR-518d-5p; this miR-518d-5p/LIN28B/DLL3 axis regulates SCLC cell proliferation and migration.","method":"RIP assay (LIN28B-DLL3 mRNA interaction), miRNA overexpression/inhibition, rescue assays in SCLC cell lines","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 3 — RNA-binding protein interaction with functional rescue, single lab","pmids":["31079917"],"is_preprint":false},{"year":2021,"finding":"Gm364 (a multi-pass transmembrane protein) directly binds and anchors the ubiquitin ligase MIB2 on the membrane, which then ubiquitinates and activates DLL3; activated DLL3 binds and activates Notch2, whose intracellular domain (NICD2) directly activates AKT to regulate oocyte meiosis and quality.","method":"Global Gm364 knockout mouse, co-immunoprecipitation, ubiquitination assays, oocyte phenotyping (ROS, mitochondrial membrane potential, aneuploidy)","journal":"Cell Death and Differentiation","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse with mechanistic chain (MIB2→DLL3 ubiquitination→Notch2→AKT) supported by Co-IP and functional phenotype, single lab","pmids":["34635817"],"is_preprint":false},{"year":2022,"finding":"DLL3 and LFNG cooperate in the segmentation clock: loss of Dll3 is epistatic to loss of Lfng in the presomitic mesoderm, causing strong reductions in Notch activity in the caudal PSM; LFNG directly modifies EGF repeats on DLL1 and DLL3; DLL3 expression in cells co-expressing DLL1 and NOTCH1 potentiates signal-sending activity in a manner modulated by LFNG, suggesting coordinated regulation of oscillatory Notch activation via glycosylation and cis-inhibition.","method":"Genetic epistasis analysis (Dll3/Lfng compound mutants), biochemical demonstration of LFNG modification of DLL1 and DLL3 EGF repeats, cell-based Notch signaling assays","journal":"Developmental Biology","confidence":"High","confidence_rationale":"Tier 1-2 — epistasis in multiple compound mutants plus direct biochemical evidence of glycosylation, multiple methods","pmids":["35429490"],"is_preprint":false},{"year":2022,"finding":"High levels of DLL3 in SCLC cells promote expansion of a cell population with lower expression of both neuroendocrine and non-neuroendocrine markers, acting as a biomarker of neuroendocrine state and regulator of cell-cell Notch interactions; this was demonstrated using a single-chain variable fragment (scFv) to track DLL3 in vivo and a mouse SCLC model with inducible DLL3 expression.","method":"Mathematical modeling, in vivo DLL3 tracking with scFv, inducible DLL3 mouse SCLC model, cell population analysis","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — inducible in vivo model with defined population-level phenotype, single lab","pmids":["36483011"],"is_preprint":false}],"current_model":"DLL3 is an atypical/divergent DSL Notch ligand that, unlike canonical Delta ligands, does not bind Notch receptors in trans or activate Notch signaling; instead it acts as a dedicated cis-inhibitor of Notch signaling in signal-sending cells, a property dependent on its intracellular domain (which lacks lysines and cannot be ubiquitinated for transendocytosis) and on O-fucosylation of its EGF-like repeats by POFUT1 (further modified by Lunatic fringe); in the presomitic mesoderm DLL3 functions together with LFNG to modulate oscillatory Notch activation in the segmentation clock, regulating somite boundary formation and rostrocaudal patterning via feedback loops with Mesp2 and DLL1; in neural development DLL3 expression is driven by Ascl1/Neurog2 transcription factors and is downstream of the N-Myc pathway (regulated by ubiquitin ligase Huwe1), promoting neurogenesis; in SCLC and other neuroendocrine tumors, DLL3 is aberrantly expressed on the cell surface (upregulated by ASCL1), promotes tumor cell migration and invasion through SNAI1 upregulation, and serves as a tumor-specific therapeutic target."},"narrative":{"teleology":[{"year":1997,"claim":"Initial gain-of-function studies in Xenopus established DLL3 as a functional Delta homologue capable of activating Notch and inhibiting neurogenesis when overexpressed, framing it as a conventional Notch ligand — a view later overturned.","evidence":"Ectopic expression of mouse Dll3 in Xenopus embryos","pmids":["9272948"],"confidence":"Medium","gaps":["Overexpression artifacts may not reflect endogenous function","No loss-of-function data","No binding mode characterized"]},{"year":1998,"claim":"Positional cloning of the pudgy mouse mutation revealed that Dll3 loss disrupts somite boundary formation and rostrocaudal patterning, establishing its non-redundant requirement in the Notch-dependent segmentation pathway.","evidence":"Positional cloning, complementation testing, and molecular marker analysis in pudgy mutant mice","pmids":["9662403"],"confidence":"High","gaps":["Mechanism of DLL3 action in somitogenesis unclear","Relationship to other Delta ligands not resolved"]},{"year":2000,"claim":"Human genetic studies linked loss-of-function DLL3 mutations to autosomal recessive spondylocostal dysostosis, confirming the conserved requirement for DLL3 in vertebral segmentation and pinpointing the EGF-like repeat domain as functionally critical.","evidence":"Sequencing of DLL3 in spondylocostal dysostosis families identifying truncating and missense mutations","pmids":["10742114"],"confidence":"High","gaps":["Biochemical consequence of individual EGF-repeat mutations not tested","No structure-function analysis"]},{"year":2002,"claim":"Targeted Dll3 null alleles demonstrated that DLL3 is required for proper oscillatory expression of segmentation clock genes (Lfng, Hes1, Hes5, Hey1), placing DLL3 upstream of the oscillatory machinery rather than merely responding to it.","evidence":"Gene targeting (null allele) with in situ hybridization of cycling genes in mouse embryos","pmids":["11923214"],"confidence":"High","gaps":["Whether DLL3 directly modulates the clock or acts indirectly through Notch signaling levels was unclear"]},{"year":2003,"claim":"Genetic epistasis between Dll1, Dll3, and Mesp2 revealed that these two Delta ligands have non-redundant, potentially counteracting roles in somite patterning, with Mesp2 acting downstream of both.","evidence":"Compound mutant mouse analysis with gene expression profiling","pmids":["12900443"],"confidence":"High","gaps":["Molecular basis for counteracting functions not identified","Direct protein interactions not tested"]},{"year":2005,"claim":"The pivotal mechanistic question — whether DLL3 is a Notch activator or inhibitor — was resolved: DLL3 does not bind Notch in trans or activate signaling but instead cell-autonomously inhibits Notch in cis, explaining the paradoxical loss-of-function phenotype and redefining DLL3 as a dedicated cis-inhibitor.","evidence":"Multiple Notch activation, trans-binding, co-culture signaling, Xenopus neurogenesis, and neural progenitor differentiation assays","pmids":["16144902"],"confidence":"High","gaps":["Structural basis for inability to signal in trans unknown","Mechanism of cis-inhibition at the molecular level unresolved"]},{"year":2008,"claim":"The inability of DLL3 to activate Notch was traced to its lysine-free intracellular domain, which cannot mediate ubiquitin-dependent transendocytosis of the Notch extracellular domain — the mechanical step required for signal activation — even when the ectodomain is replaced with that of DLL1.","evidence":"Chimeric DLL1/DLL3 ligand construction with endocytosis, recycling, Notch1 binding, and transendocytosis assays in cell culture","pmids":["18676613"],"confidence":"High","gaps":["Whether additional ectodomain features contribute to the lack of trans-signaling not fully excluded","In vivo validation of chimera phenotype not performed"]},{"year":2009,"claim":"Three independent studies placed DLL3 within defined transcriptional and signaling networks: Ascl1/Neurog2 directly bind the Dll3 promoter to drive expression in neural tube; the Huwe1–N-Myc axis regulates DLL3 upstream to control neural stem cell expansion; and DLL3 is specifically required for Nrarp oscillation independently of Lfng.","evidence":"Transgenic reporters with E-box mutagenesis plus in vitro binding (Dll3 promoter); conditional Huwe1 KO with cortical neurogenesis phenotyping; Dll3/Lfng null expression analysis","pmids":["19389376","19686682","19268448"],"confidence":"High","gaps":["Whether Ascl1-driven DLL3 expression is direct in presomitic mesoderm not tested","Downstream effectors linking DLL3 cis-inhibition to Nrarp oscillation unknown"]},{"year":2015,"claim":"O-fucosylation of DLL3 EGF repeats by POFUT1 was shown to be essential for in vivo somitogenesis function but dispensable for cis-inhibition in vitro, revealing a separable requirement for glycosylation during segmentation clock operation; DLL3 and LFNG physically interact in the trans-Golgi.","evidence":"Site-directed mutagenesis of O-fucosylation sites, transgenic rescue in Dll3 null embryos, co-immunoprecipitation, in vitro Notch inhibition assays","pmids":["25856312"],"confidence":"High","gaps":["Molecular basis for why O-fucosylation is required in vivo but not in vitro unclear","Structural details of DLL3-LFNG interaction not resolved"]},{"year":2019,"claim":"In SCLC, DLL3 was shown to have a tumor-promoting role: it drives migration and invasion through SNAI1 upregulation, and DLL3 mRNA is stabilized by LIN28B within a miR-518d-5p regulatory axis.","evidence":"siRNA/overexpression in SCLC lines with transwell assays and xenografts; RIP assay for LIN28B-DLL3 mRNA binding","pmids":["30874360","31079917"],"confidence":"Medium","gaps":["Mechanism linking DLL3 to SNAI1 transcription not defined","Whether DLL3's tumor role depends on cis-inhibition of Notch or an independent pathway is unresolved"]},{"year":2022,"claim":"Compound Dll3/Lfng mutant analysis established that DLL3 and LFNG cooperate in the segmentation clock with DLL3 loss epistatic to LFNG loss, and that DLL3 in cells co-expressing DLL1 and NOTCH1 potentiates signal-sending activity in a glycosylation-modulated manner, providing an integrated model of oscillatory Notch regulation.","evidence":"Genetic epistasis (compound mutants), biochemical demonstration of LFNG modification of DLL3 EGF repeats, cell-based Notch signaling assays","pmids":["35429490"],"confidence":"High","gaps":["How cis-inhibition and signal-sending potentiation are balanced quantitatively during oscillation remains unresolved","Direct visualization of DLL3 dynamics in the clock is lacking"]},{"year":null,"claim":"Key unresolved questions include the structural basis for DLL3's exclusive cis-inhibitory mode, the mechanism by which DLL3 upregulates SNAI1 in tumor cells, and whether DLL3's role in SCLC is Notch-dependent or involves Notch-independent signaling.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of DLL3 alone or in complex with Notch","Molecular pathway connecting DLL3 to SNAI1 in SCLC undefined","Whether DLL3 ubiquitination by MIB2 (observed in oocytes) is generalizable to other tissues is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,8,16]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,8,13]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[12]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,3,6,8,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,2,3,4,12,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,17]}],"complexes":[],"partners":["LFNG","DLL1","NOTCH1","ASCL1","NEUROG2","SNAI1","LIN28B","MESP2"],"other_free_text":[]},"mechanistic_narrative":"DLL3 is a divergent Delta/Serrate/LAG-2 (DSL) family Notch ligand that functions as a dedicated cis-inhibitor of Notch signaling rather than a canonical trans-activating ligand, playing essential roles in somitogenesis, neurogenesis, and neuroendocrine tumor biology. Unlike DLL1, DLL3 does not bind Notch receptors in trans or trigger transendocytosis of the Notch extracellular domain — a deficiency traced to its lysine-free intracellular domain, which cannot be ubiquitinated for the force-generating endocytic step required for Notch activation [PMID:16144902, PMID:18676613]. In the presomitic mesoderm, DLL3 cooperates with Lunatic fringe (LFNG) to modulate oscillatory Notch activation in the segmentation clock; its O-fucosylation by POFUT1 is dispensable for cis-inhibition in vitro but essential for somitogenesis in vivo, and loss-of-function mutations in DLL3 cause autosomal recessive spondylocostal dysostosis in humans [PMID:10742114, PMID:25856312, PMID:35429490]. DLL3 transcription is driven by Ascl1/Neurog2 in neural progenitors and is positioned downstream of N-Myc (regulated by Huwe1) to promote neurogenesis; in SCLC, DLL3 is aberrantly surface-expressed and promotes tumor cell migration and invasion through upregulation of SNAI1 [PMID:19389376, PMID:19686682, PMID:30874360]."},"prefetch_data":{"uniprot":{"accession":"Q9NYJ7","full_name":"Delta-like protein 3","aliases":["Drosophila Delta homolog 3","Delta3"],"length_aa":618,"mass_kda":64.6,"function":"Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm (By similarity)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q9NYJ7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DLL3","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/DLL3","total_profiled":1310},"omim":[{"mim_id":"609813","title":"SPONDYLOCOSTAL DYSOSTOSIS 3, AUTOSOMAL RECESSIVE; SCDO3","url":"https://www.omim.org/entry/609813"},{"mim_id":"608681","title":"SPONDYLOCOSTAL DYSOSTOSIS 2, AUTOSOMAL RECESSIVE; SCDO2","url":"https://www.omim.org/entry/608681"},{"mim_id":"608059","title":"HES FAMILY bHLH TRANSCRIPTION FACTOR 7; HES7","url":"https://www.omim.org/entry/608059"},{"mim_id":"605195","title":"MESODERM POSTERIOR BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTOR 2; MESP2","url":"https://www.omim.org/entry/605195"},{"mim_id":"605189","title":"DICKKOPF WNT SIGNALING PATHWAY INHIBITOR 1; DKK1","url":"https://www.omim.org/entry/605189"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Golgi apparatus","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":27.1}],"url":"https://www.proteinatlas.org/search/DLL3"},"hgnc":{"alias_symbol":["SCDO1"],"prev_symbol":[]},"alphafold":{"accession":"Q9NYJ7","domains":[{"cath_id":"2.60.40.3510","chopping":"25-191","consensus_level":"high","plddt":79.8634,"start":25,"end":191},{"cath_id":"2.10.25.10","chopping":"432-469","consensus_level":"medium","plddt":80.2908,"start":432,"end":469}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYJ7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYJ7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYJ7-F1-predicted_aligned_error_v6.png","plddt_mean":65.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DLL3","jax_strain_url":"https://www.jax.org/strain/search?query=DLL3"},"sequence":{"accession":"Q9NYJ7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NYJ7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NYJ7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYJ7"}},"corpus_meta":[{"pmid":"26311731","id":"PMC_26311731","title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.","date":"2015","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26311731","citation_count":473,"is_preprint":false},{"pmid":"27932068","id":"PMC_27932068","title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.","date":"2016","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27932068","citation_count":452,"is_preprint":false},{"pmid":"9272948","id":"PMC_9272948","title":"Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo.","date":"1997","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9272948","citation_count":320,"is_preprint":false},{"pmid":"10742114","id":"PMC_10742114","title":"Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis.","date":"2000","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10742114","citation_count":306,"is_preprint":false},{"pmid":"31506387","id":"PMC_31506387","title":"Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31506387","citation_count":258,"is_preprint":false},{"pmid":"36689692","id":"PMC_36689692","title":"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.","date":"2023","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36689692","citation_count":237,"is_preprint":false},{"pmid":"9662403","id":"PMC_9662403","title":"The mouse pudgy mutation disrupts Delta homologue Dll3 and initiation of early somite boundaries.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9662403","citation_count":237,"is_preprint":false},{"pmid":"16144902","id":"PMC_16144902","title":"The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands.","date":"2005","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16144902","citation_count":233,"is_preprint":false},{"pmid":"33607312","id":"PMC_33607312","title":"Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.","date":"2021","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33607312","citation_count":223,"is_preprint":false},{"pmid":"33203642","id":"PMC_33203642","title":"AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33203642","citation_count":190,"is_preprint":false},{"pmid":"31215500","id":"PMC_31215500","title":"DLL3: an emerging target in small cell lung cancer.","date":"2019","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31215500","citation_count":189,"is_preprint":false},{"pmid":"11923214","id":"PMC_11923214","title":"Axial skeletal defects caused by mutation in the spondylocostal dysplasia/pudgy gene Dll3 are associated with disruption of the segmentation clock within the presomitic mesoderm.","date":"2002","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11923214","citation_count":177,"is_preprint":false},{"pmid":"36951942","id":"PMC_36951942","title":"IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36951942","citation_count":144,"is_preprint":false},{"pmid":"19686682","id":"PMC_19686682","title":"The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain.","date":"2009","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/19686682","citation_count":139,"is_preprint":false},{"pmid":"37355629","id":"PMC_37355629","title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.","date":"2023","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37355629","citation_count":130,"is_preprint":false},{"pmid":"12746394","id":"PMC_12746394","title":"Novel mutations in DLL3, a somitogenesis gene encoding a ligand for the Notch signalling pathway, cause a consistent pattern of abnormal vertebral segmentation in spondylocostal dysostosis.","date":"2003","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12746394","citation_count":110,"is_preprint":false},{"pmid":"28487384","id":"PMC_28487384","title":"Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28487384","citation_count":92,"is_preprint":false},{"pmid":"19389376","id":"PMC_19389376","title":"Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19389376","citation_count":89,"is_preprint":false},{"pmid":"32554516","id":"PMC_32554516","title":"A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32554516","citation_count":79,"is_preprint":false},{"pmid":"30874360","id":"PMC_30874360","title":"DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.","date":"2019","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/30874360","citation_count":79,"is_preprint":false},{"pmid":"12900443","id":"PMC_12900443","title":"Feedback loops comprising Dll1, Dll3 and Mesp2, and differential involvement of Psen1 are essential for rostrocaudal patterning of somites.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12900443","citation_count":77,"is_preprint":false},{"pmid":"18676613","id":"PMC_18676613","title":"The intracellular region of Notch ligands Dll1 and Dll3 regulates their trafficking and signaling activity.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18676613","citation_count":71,"is_preprint":false},{"pmid":"35088475","id":"PMC_35088475","title":"CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.","date":"2022","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/35088475","citation_count":68,"is_preprint":false},{"pmid":"35983951","id":"PMC_35983951","title":"DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.","date":"2022","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/35983951","citation_count":66,"is_preprint":false},{"pmid":"32554616","id":"PMC_32554616","title":"Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32554616","citation_count":64,"is_preprint":false},{"pmid":"32745892","id":"PMC_32745892","title":"International real-world study of DLL3 expression in patients with small cell lung cancer.","date":"2020","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/32745892","citation_count":62,"is_preprint":false},{"pmid":"30397180","id":"PMC_30397180","title":"Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30397180","citation_count":60,"is_preprint":false},{"pmid":"36645960","id":"PMC_36645960","title":"Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36645960","citation_count":54,"is_preprint":false},{"pmid":"35815644","id":"PMC_35815644","title":"Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.","date":"2022","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35815644","citation_count":54,"is_preprint":false},{"pmid":"31678831","id":"PMC_31678831","title":"DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.","date":"2019","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/31678831","citation_count":53,"is_preprint":false},{"pmid":"36351060","id":"PMC_36351060","title":"Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36351060","citation_count":52,"is_preprint":false},{"pmid":"31981983","id":"PMC_31981983","title":"Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.","date":"2020","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31981983","citation_count":50,"is_preprint":false},{"pmid":"31068386","id":"PMC_31068386","title":"Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).","date":"2019","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/31068386","citation_count":48,"is_preprint":false},{"pmid":"25856312","id":"PMC_25856312","title":"O-fucosylation of DLL3 is required for its function during somitogenesis.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25856312","citation_count":46,"is_preprint":false},{"pmid":"29975944","id":"PMC_29975944","title":"LncRNA LINC00311 Promotes the Proliferation and Differentiation of Osteoclasts in Osteoporotic Rats Through the Notch Signaling Pathway by Targeting DLL3.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29975944","citation_count":46,"is_preprint":false},{"pmid":"36692420","id":"PMC_36692420","title":"Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.","date":"2023","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/36692420","citation_count":45,"is_preprint":false},{"pmid":"33409812","id":"PMC_33409812","title":"Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.","date":"2021","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33409812","citation_count":43,"is_preprint":false},{"pmid":"19268448","id":"PMC_19268448","title":"Cyclical expression of the Notch/Wnt regulator Nrarp requires modulation by Dll3 in somitogenesis.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19268448","citation_count":40,"is_preprint":false},{"pmid":"38730427","id":"PMC_38730427","title":"DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.","date":"2024","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38730427","citation_count":39,"is_preprint":false},{"pmid":"36483011","id":"PMC_36483011","title":"DLL3 regulates Notch signaling in small cell lung cancer.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/36483011","citation_count":39,"is_preprint":false},{"pmid":"15170697","id":"PMC_15170697","title":"Dll3 pudgy mutation differentially disrupts dynamic expression of somite genes.","date":"2004","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/15170697","citation_count":39,"is_preprint":false},{"pmid":"38950555","id":"PMC_38950555","title":"Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.","date":"2024","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38950555","citation_count":37,"is_preprint":false},{"pmid":"17849441","id":"PMC_17849441","title":"Dll3 and Notch1 genetic interactions model axial segmental and craniofacial malformations of human birth defects.","date":"2007","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/17849441","citation_count":33,"is_preprint":false},{"pmid":"31079917","id":"PMC_31079917","title":"DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31079917","citation_count":32,"is_preprint":false},{"pmid":"31447000","id":"PMC_31447000","title":"Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.","date":"2019","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/31447000","citation_count":31,"is_preprint":false},{"pmid":"37844745","id":"PMC_37844745","title":"Saikosaponin a activates tet1/dll3/notch1 signalling and promotes hippocampal neurogenesis to improve depression-like behavior in mice.","date":"2023","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37844745","citation_count":30,"is_preprint":false},{"pmid":"37694295","id":"PMC_37694295","title":"Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC).","date":"2023","source":"Journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37694295","citation_count":30,"is_preprint":false},{"pmid":"30232719","id":"PMC_30232719","title":"Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate.","date":"2018","source":"Drugs in R&D","url":"https://pubmed.ncbi.nlm.nih.gov/30232719","citation_count":29,"is_preprint":false},{"pmid":"38760413","id":"PMC_38760413","title":"Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.","date":"2024","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38760413","citation_count":28,"is_preprint":false},{"pmid":"17041936","id":"PMC_17041936","title":"DLL3 as a candidate gene for vertebral malformations.","date":"2006","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/17041936","citation_count":27,"is_preprint":false},{"pmid":"12791036","id":"PMC_12791036","title":"A cluster of autosomal recessive spondylocostal dysostosis caused by three newly identified DLL3 mutations segregating in a small village.","date":"2003","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12791036","citation_count":27,"is_preprint":false},{"pmid":"31186700","id":"PMC_31186700","title":"NOTCH2/NOTCH3/DLL3/MAML1/ADAM17 signaling network is associated with ovarian cancer.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31186700","citation_count":25,"is_preprint":false},{"pmid":"28705113","id":"PMC_28705113","title":"EGFL7 participates in regulating biological behavior of growth hormone-secreting pituitary adenomas via Notch2/DLL3 signaling pathway.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28705113","citation_count":25,"is_preprint":false},{"pmid":"31819500","id":"PMC_31819500","title":"Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31819500","citation_count":24,"is_preprint":false},{"pmid":"32691982","id":"PMC_32691982","title":"DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.","date":"2020","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32691982","citation_count":23,"is_preprint":false},{"pmid":"38670552","id":"PMC_38670552","title":"HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors.","date":"2024","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38670552","citation_count":22,"is_preprint":false},{"pmid":"31109352","id":"PMC_31109352","title":"Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.","date":"2019","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31109352","citation_count":22,"is_preprint":false},{"pmid":"30958693","id":"PMC_30958693","title":"Delta-like Protein 3 Prevalence in Small Cell Lung Cancer and DLL3 (SP347) Assay Characteristics.","date":"2019","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30958693","citation_count":22,"is_preprint":false},{"pmid":"40075480","id":"PMC_40075480","title":"Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer.","date":"2025","source":"Experimental hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40075480","citation_count":21,"is_preprint":false},{"pmid":"38558120","id":"PMC_38558120","title":"Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.","date":"2024","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/38558120","citation_count":20,"is_preprint":false},{"pmid":"39423775","id":"PMC_39423775","title":"Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.","date":"2024","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/39423775","citation_count":20,"is_preprint":false},{"pmid":"39558076","id":"PMC_39558076","title":"Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms.","date":"2024","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39558076","citation_count":19,"is_preprint":false},{"pmid":"27308627","id":"PMC_27308627","title":"Toppling high-grade pulmonary neuroendocrine tumors with a DLL3-targeted trojan horse.","date":"2016","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27308627","citation_count":19,"is_preprint":false},{"pmid":"20503311","id":"PMC_20503311","title":"Autosomal dominant spondylocostal dysostosis in three generations of a Macedonian family: Negative mutation analysis of DLL3, MESP2, HES7, and LFNG.","date":"2010","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/20503311","citation_count":19,"is_preprint":false},{"pmid":"39326646","id":"PMC_39326646","title":"DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review.","date":"2024","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/39326646","citation_count":18,"is_preprint":false},{"pmid":"38940283","id":"PMC_38940283","title":"FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models.","date":"2024","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38940283","citation_count":18,"is_preprint":false},{"pmid":"11118901","id":"PMC_11118901","title":"Dynamic expression patterns of the pudgy/spondylocostal dysostosis gene Dll3 in the developing nervous system.","date":"2001","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11118901","citation_count":18,"is_preprint":false},{"pmid":"33074129","id":"PMC_33074129","title":"Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression.","date":"2020","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33074129","citation_count":18,"is_preprint":false},{"pmid":"34931456","id":"PMC_34931456","title":"ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.","date":"2021","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34931456","citation_count":18,"is_preprint":false},{"pmid":"39143619","id":"PMC_39143619","title":"DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39143619","citation_count":17,"is_preprint":false},{"pmid":"11441047","id":"PMC_11441047","title":"Differential and overlapping expression patterns of X-dll3 and Pax-6 genes suggest distinct roles in olfactory system development of the African clawed frog Xenopus laevis.","date":"2001","source":"The Journal of experimental biology","url":"https://pubmed.ncbi.nlm.nih.gov/11441047","citation_count":16,"is_preprint":false},{"pmid":"33617464","id":"PMC_33617464","title":"DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas.","date":"2021","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/33617464","citation_count":15,"is_preprint":false},{"pmid":"39703856","id":"PMC_39703856","title":"Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions.","date":"2024","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39703856","citation_count":14,"is_preprint":false},{"pmid":"38469682","id":"PMC_38469682","title":"TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer.","date":"2024","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38469682","citation_count":14,"is_preprint":false},{"pmid":"34635817","id":"PMC_34635817","title":"Gm364 coordinates MIB2/DLL3/Notch2 to regulate female fertility through AKT activation.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/34635817","citation_count":14,"is_preprint":false},{"pmid":"33835770","id":"PMC_33835770","title":"Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.","date":"2021","source":"Bioconjugate chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33835770","citation_count":13,"is_preprint":false},{"pmid":"37731022","id":"PMC_37731022","title":"Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.","date":"2023","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37731022","citation_count":13,"is_preprint":false},{"pmid":"36034078","id":"PMC_36034078","title":"Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity.","date":"2022","source":"Research in pharmaceutical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36034078","citation_count":12,"is_preprint":false},{"pmid":"15153675","id":"PMC_15153675","title":"New mutant mouse with skeletal deformities caused by mutation in delta like 3 (Dll3) gene.","date":"2004","source":"Experimental animals","url":"https://pubmed.ncbi.nlm.nih.gov/15153675","citation_count":12,"is_preprint":false},{"pmid":"40153138","id":"PMC_40153138","title":"DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms.","date":"2025","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40153138","citation_count":11,"is_preprint":false},{"pmid":"35429490","id":"PMC_35429490","title":"Lfng and Dll3 cooperate to modulate protein interactions in cis and coordinate oscillatory Notch pathway activation in the segmentation clock.","date":"2022","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35429490","citation_count":11,"is_preprint":false},{"pmid":"39874041","id":"PMC_39874041","title":"Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting.","date":"2025","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39874041","citation_count":10,"is_preprint":false},{"pmid":"39865119","id":"PMC_39865119","title":"Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39865119","citation_count":9,"is_preprint":false},{"pmid":"36381237","id":"PMC_36381237","title":"Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.","date":"2022","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36381237","citation_count":9,"is_preprint":false},{"pmid":"36530878","id":"PMC_36530878","title":"Harnessing DLL3 inhibition: From old promises to new therapeutic horizons.","date":"2022","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36530878","citation_count":8,"is_preprint":false},{"pmid":"35477310","id":"PMC_35477310","title":"Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin.","date":"2022","source":"Expert review of anticancer therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35477310","citation_count":6,"is_preprint":false},{"pmid":"38346470","id":"PMC_38346470","title":"Tet1/DLL3/Notch1 signal pathway affects hippocampal neurogenesis and regulates depression-like behaviour in mice.","date":"2024","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38346470","citation_count":6,"is_preprint":false},{"pmid":"39619276","id":"PMC_39619276","title":"First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report.","date":"2024","source":"JTO clinical and research reports","url":"https://pubmed.ncbi.nlm.nih.gov/39619276","citation_count":6,"is_preprint":false},{"pmid":"39589690","id":"PMC_39589690","title":"Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study.","date":"2024","source":"Clinical pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/39589690","citation_count":6,"is_preprint":false},{"pmid":"40261494","id":"PMC_40261494","title":"Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer.","date":"2025","source":"Clinical pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/40261494","citation_count":5,"is_preprint":false},{"pmid":"40284515","id":"PMC_40284515","title":"Targeting DLL3: Innovative Strategies for Tumor Treatment.","date":"2025","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/40284515","citation_count":5,"is_preprint":false},{"pmid":"37323197","id":"PMC_37323197","title":"Identification of a Novel Nonsense Variant in the DLL3 Gene Underlying Spondylocostal Dysostosis in a Consanguineous Pakistani Family.","date":"2023","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/37323197","citation_count":5,"is_preprint":false},{"pmid":"39392394","id":"PMC_39392394","title":"Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at SCLC.","date":"2024","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/39392394","citation_count":5,"is_preprint":false},{"pmid":"38260492","id":"PMC_38260492","title":"First-in-human imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate.","date":"2024","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38260492","citation_count":4,"is_preprint":false},{"pmid":"38468968","id":"PMC_38468968","title":"Expression patterns and clinical implications of PDL1 and DLL3 biomarkers in small cell lung cancer retrospectively studied: Insights for therapeutic strategies and survival prediction.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/38468968","citation_count":4,"is_preprint":false},{"pmid":"37179118","id":"PMC_37179118","title":"Biological and immunological significance of DLL3 expression in different tumor tissues: a pan-cancer analysis.","date":"2023","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/37179118","citation_count":3,"is_preprint":false},{"pmid":"35382168","id":"PMC_35382168","title":"Elevated DLL3 in stomach cancer by tumor-associated macrophages enhances cancer-cell proliferation and cytokine secretion of macrophages.","date":"2021","source":"Gastroenterology report","url":"https://pubmed.ncbi.nlm.nih.gov/35382168","citation_count":3,"is_preprint":false},{"pmid":"40066092","id":"PMC_40066092","title":"Engineered exosomes restore miR-508-5p expression in uterine corpus endometrial carcinoma and reduce tumor progression and metastasis by targeting DLL3.","date":"2025","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40066092","citation_count":3,"is_preprint":false},{"pmid":"40699376","id":"PMC_40699376","title":"Expression of DLL3 and SEZ6 in the Spectrum of Neuroendocrine Neoplasia.","date":"2025","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40699376","citation_count":2,"is_preprint":false},{"pmid":"32488689","id":"PMC_32488689","title":"Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry.","date":"2020","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32488689","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56457,"output_tokens":4645,"usd":0.119523},"stage2":{"model":"claude-opus-4-6","input_tokens":8122,"output_tokens":3033,"usd":0.174652},"total_usd":0.294175,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Mouse Dll3, a divergent Delta homologue, can activate the Notch receptor and inhibit primary neurogenesis when ectopically expressed in Xenopus, demonstrating it is a functional Delta homologue capable of activating Notch signaling.\",\n      \"method\": \"Ectopic expression in Xenopus embryos (gain-of-function assay)\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional in vivo assay in Xenopus, single lab, single method\",\n      \"pmids\": [\"9272948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Loss-of-function mutation in Dll3 (pudgy mouse) disrupts proper formation of morphological borders in early somite formation and rostral-caudal compartment boundaries within somites, establishing Dll3 as required for initiation of patterning of vertebrate paraxial mesoderm via a Notch-signalling pathway.\",\n      \"method\": \"Positional cloning, complementation testing, histological and molecular marker analyses in pudgy (pu) mouse mutants\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — positional cloning plus in vivo loss-of-function with defined molecular phenotype, foundational paper with 237 citations\",\n      \"pmids\": [\"9662403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Mutations in human DLL3, including truncating mutations in conserved extracellular domains and a missense mutation in the fifth EGF repeat, cause autosomal recessive spondylocostal dysostosis, establishing that the EGF-like repeat domain is functionally critical.\",\n      \"method\": \"Mutational analysis (sequencing) of DLL3 in spondylocostal dysostosis families; functional inference from domain conservation\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human genetics with multiple families and domain-level functional inference, replicated across families, 306 citations\",\n      \"pmids\": [\"10742114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Loss-of-function mutation in mouse Dll3 (targeted null allele Dll3neo) causes disruption of the segmentation clock in the presomitic mesoderm, evidenced by perturbed oscillatory expression of Lfng, Hes1, Hes5, and Hey1, resulting in delayed and irregular somite formation and loss of anteroposterior somite polarity.\",\n      \"method\": \"Gene targeting (null allele), expression analysis of cycling genes by in situ hybridization in mutant embryos\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — clean KO with multiple molecular markers of segmentation clock, well-controlled study\",\n      \"pmids\": [\"11923214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Dll1 and Dll3 operate in feedback loops with Mesp2 for rostrocaudal patterning of somites; genetic epistasis analysis shows Dll1 and Dll3 have non-redundant and potentially counteracting functions in the presomitic mesoderm, with Mesp2 acting downstream of both Notch ligands.\",\n      \"method\": \"Genetic epistasis analysis using Dll1, Dll3, Mesp2, and Psen1 mutant mice; gene expression analysis in compound mutants\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis analysis with multiple compound mutants, clear pathway placement\",\n      \"pmids\": [\"12900443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The Dll3 pudgy mutation differentially disrupts cycling (Lfng, Hes7) versus stage-specific (Hey3, Mesp2) genes in paraxial mesoderm, suggesting Dll3 participates in more than one oscillatory mechanism during somitogenesis.\",\n      \"method\": \"Expression analysis of cycling and stage-specific genes in Dll3 pudgy mutant embryos by in situ hybridization\",\n      \"journal\": \"Genesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with multiple molecular readouts, single lab\",\n      \"pmids\": [\"15170697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"DLL3 does not activate Notch signaling (unlike other DSL ligands); it does not bind Notch receptors in trans and Notch1 does not bind DLL3-expressing cells, but DLL3 cell-autonomously suppresses Notch signaling (cis-inhibition), promoting neurogenesis and inhibiting glial differentiation. Together with lunatic fringe, DLL3 modulates Notch signaling levels induced by other DSL ligands.\",\n      \"method\": \"Multiple Notch activation assays, cell-binding assays (trans-binding), co-culture signaling assays, Xenopus neurogenesis assay, mouse neural progenitor differentiation assay\",\n      \"journal\": \"Journal of Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal assays in one study demonstrating DLL3 as a dedicated Notch cis-inhibitor rather than activator; 233 citations\",\n      \"pmids\": [\"16144902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Dll3-Notch1 double heterozygous mice exhibit localized segmental vertebral anomalies and craniofacial defects not seen in single heterozygotes, demonstrating a genetic interaction between Dll3 ligand and Notch1 receptor in axial segmentation and craniofacial development.\",\n      \"method\": \"Compound mutant mouse analysis (double heterozygosity), skeletal phenotyping, microarray gene expression\",\n      \"journal\": \"Developmental Dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic interaction established by compound heterozygous phenotype, single lab\",\n      \"pmids\": [\"17849441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The intracellular domain of Dll3 (which contains no lysine) directs endocytosis and recycling via an ubiquitination-independent signal; a Dll1-Dll3 chimera (Dll1 ectodomain + Dll3 transmembrane/intracellular domain) is endocytosed, recycled, and binds Notch1 but cannot induce transendocytosis of the Notch1 extracellular region and therefore cannot activate Notch signaling, indicating that transendocytosis—not merely receptor binding—is required for Notch activation and that the Dll3 intracellular domain specifically lacks this capacity.\",\n      \"method\": \"Chimeric ligand construction, endocytosis/recycling assays, Notch1 binding assays, transendocytosis assays in cell culture\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution with chimeric molecules plus mechanistic dissection of multiple steps (endocytosis, recycling, binding, transendocytosis), multiple orthogonal methods\",\n      \"pmids\": [\"18676613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The ubiquitin ligase Huwe1 restrains neural stem cell proliferation and enables neurogenesis by suppressing the N-Myc–DLL3 cascade; loss of Huwe1 in the mouse cortex leads to uncontrolled expansion of neural stem cells associated with upregulation of DLL3, placing DLL3 downstream of N-Myc and upstream of Notch in neural stem cell regulation.\",\n      \"method\": \"Conditional Huwe1 knockout in mouse brain, loss- and gain-of-function experiments, cortical layering and neurogenesis phenotyping\",\n      \"journal\": \"Developmental Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined cellular phenotype and pathway placement (Huwe1→N-Myc→DLL3→Notch), replicated with gain-of-function\",\n      \"pmids\": [\"19686682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Dll3 is required for normal cyclical expression of Nrarp (a Notch/Wnt regulator) in the presomitic mesoderm during somitogenesis; in Dll3 null embryos Nrarp shows static (non-cycling) expression, while Lfng null embryos eventually resume Nrarp cycling, indicating that Dll3 is specifically required for Nrarp oscillation independently of Lfng.\",\n      \"method\": \"Microdissection of somitic/presomitic mesoderm, gene expression analysis by in situ hybridization in Dll3 null, Lfng null, and Wnt3a null embryos\",\n      \"journal\": \"Developmental Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function in multiple mutant backgrounds with defined target gene, single lab\",\n      \"pmids\": [\"19268448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The bHLH transcription factors Ascl1 (Mash1) and Neurog2 form novel DNA-binding complexes (including Ascl1/Ascl1 homodimers and Ascl1/Neurog2 heterodimers) that bind E-boxes in the conserved proximal Dll3 promoter to regulate Dll3 expression in the dorsal neural tube; individual E-boxes function as distinct enhancers or repressors.\",\n      \"method\": \"Transgenic mouse reporter assays, E-box mutagenesis, in vitro DNA-binding assays, loss-of-function analysis of Ascl1 and Neurog2\",\n      \"journal\": \"Developmental Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro binding assays combined with transgenic reporter and mutagenesis in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"19389376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"O-fucosylation of DLL3 EGF-like repeats 2 and 5 (at POFUT1 consensus sites) is essential for DLL3 function during somitogenesis in vivo; O-fucosylation-deficient DLL3 can still interact with LFNG, Notch1, and DLL1 and retains cis-inhibitory activity in vitro, but cannot rescue the Dll3 null somitogenesis defect, and DLL3 and LFNG interact physically within the trans-Golgi.\",\n      \"method\": \"Site-directed mutagenesis of O-fucosylation sites, transgenic rescue experiments in Dll3 null embryos, co-immunoprecipitation of DLL3 and LFNG, in vitro Notch inhibition assays\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis + in vivo rescue + co-IP + in vitro assay, multiple orthogonal methods in single study\",\n      \"pmids\": [\"25856312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DLL3 promotes migration and invasion of SCLC cells by positively regulating SNAI1 (Snail) expression; DLL3 knockdown reduced migration/invasion and SNAI1 levels, while DLL3 overexpression increased them, and SNAI1 knockdown attenuated DLL3-driven migration/invasion. DLL3 overexpression also promoted subcutaneous tumor growth in mice.\",\n      \"method\": \"Loss-of-function (siRNA knockdown) and gain-of-function (overexpression) in SCLC cell lines, transwell migration/invasion assay, SNAI1 expression analysis, mouse xenograft model\",\n      \"journal\": \"Cancer Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — both KD and OE with defined molecular (SNAI1) and cellular phenotype, in vitro and in vivo\",\n      \"pmids\": [\"30874360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DLL3 mRNA is stabilized by the RNA-binding protein LIN28B, and both LIN28B and DLL3 are downstream targets of miR-518d-5p; this miR-518d-5p/LIN28B/DLL3 axis regulates SCLC cell proliferation and migration.\",\n      \"method\": \"RIP assay (LIN28B-DLL3 mRNA interaction), miRNA overexpression/inhibition, rescue assays in SCLC cell lines\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — RNA-binding protein interaction with functional rescue, single lab\",\n      \"pmids\": [\"31079917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Gm364 (a multi-pass transmembrane protein) directly binds and anchors the ubiquitin ligase MIB2 on the membrane, which then ubiquitinates and activates DLL3; activated DLL3 binds and activates Notch2, whose intracellular domain (NICD2) directly activates AKT to regulate oocyte meiosis and quality.\",\n      \"method\": \"Global Gm364 knockout mouse, co-immunoprecipitation, ubiquitination assays, oocyte phenotyping (ROS, mitochondrial membrane potential, aneuploidy)\",\n      \"journal\": \"Cell Death and Differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with mechanistic chain (MIB2→DLL3 ubiquitination→Notch2→AKT) supported by Co-IP and functional phenotype, single lab\",\n      \"pmids\": [\"34635817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DLL3 and LFNG cooperate in the segmentation clock: loss of Dll3 is epistatic to loss of Lfng in the presomitic mesoderm, causing strong reductions in Notch activity in the caudal PSM; LFNG directly modifies EGF repeats on DLL1 and DLL3; DLL3 expression in cells co-expressing DLL1 and NOTCH1 potentiates signal-sending activity in a manner modulated by LFNG, suggesting coordinated regulation of oscillatory Notch activation via glycosylation and cis-inhibition.\",\n      \"method\": \"Genetic epistasis analysis (Dll3/Lfng compound mutants), biochemical demonstration of LFNG modification of DLL1 and DLL3 EGF repeats, cell-based Notch signaling assays\",\n      \"journal\": \"Developmental Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — epistasis in multiple compound mutants plus direct biochemical evidence of glycosylation, multiple methods\",\n      \"pmids\": [\"35429490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"High levels of DLL3 in SCLC cells promote expansion of a cell population with lower expression of both neuroendocrine and non-neuroendocrine markers, acting as a biomarker of neuroendocrine state and regulator of cell-cell Notch interactions; this was demonstrated using a single-chain variable fragment (scFv) to track DLL3 in vivo and a mouse SCLC model with inducible DLL3 expression.\",\n      \"method\": \"Mathematical modeling, in vivo DLL3 tracking with scFv, inducible DLL3 mouse SCLC model, cell population analysis\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — inducible in vivo model with defined population-level phenotype, single lab\",\n      \"pmids\": [\"36483011\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DLL3 is an atypical/divergent DSL Notch ligand that, unlike canonical Delta ligands, does not bind Notch receptors in trans or activate Notch signaling; instead it acts as a dedicated cis-inhibitor of Notch signaling in signal-sending cells, a property dependent on its intracellular domain (which lacks lysines and cannot be ubiquitinated for transendocytosis) and on O-fucosylation of its EGF-like repeats by POFUT1 (further modified by Lunatic fringe); in the presomitic mesoderm DLL3 functions together with LFNG to modulate oscillatory Notch activation in the segmentation clock, regulating somite boundary formation and rostrocaudal patterning via feedback loops with Mesp2 and DLL1; in neural development DLL3 expression is driven by Ascl1/Neurog2 transcription factors and is downstream of the N-Myc pathway (regulated by ubiquitin ligase Huwe1), promoting neurogenesis; in SCLC and other neuroendocrine tumors, DLL3 is aberrantly expressed on the cell surface (upregulated by ASCL1), promotes tumor cell migration and invasion through SNAI1 upregulation, and serves as a tumor-specific therapeutic target.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"DLL3 is a divergent Delta/Serrate/LAG-2 (DSL) family Notch ligand that functions as a dedicated cis-inhibitor of Notch signaling rather than a canonical trans-activating ligand, playing essential roles in somitogenesis, neurogenesis, and neuroendocrine tumor biology. Unlike DLL1, DLL3 does not bind Notch receptors in trans or trigger transendocytosis of the Notch extracellular domain — a deficiency traced to its lysine-free intracellular domain, which cannot be ubiquitinated for the force-generating endocytic step required for Notch activation [PMID:16144902, PMID:18676613]. In the presomitic mesoderm, DLL3 cooperates with Lunatic fringe (LFNG) to modulate oscillatory Notch activation in the segmentation clock; its O-fucosylation by POFUT1 is dispensable for cis-inhibition in vitro but essential for somitogenesis in vivo, and loss-of-function mutations in DLL3 cause autosomal recessive spondylocostal dysostosis in humans [PMID:10742114, PMID:25856312, PMID:35429490]. DLL3 transcription is driven by Ascl1/Neurog2 in neural progenitors and is positioned downstream of N-Myc (regulated by Huwe1) to promote neurogenesis; in SCLC, DLL3 is aberrantly surface-expressed and promotes tumor cell migration and invasion through upregulation of SNAI1 [PMID:19389376, PMID:19686682, PMID:30874360].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Initial gain-of-function studies in Xenopus established DLL3 as a functional Delta homologue capable of activating Notch and inhibiting neurogenesis when overexpressed, framing it as a conventional Notch ligand — a view later overturned.\",\n      \"evidence\": \"Ectopic expression of mouse Dll3 in Xenopus embryos\",\n      \"pmids\": [\"9272948\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression artifacts may not reflect endogenous function\", \"No loss-of-function data\", \"No binding mode characterized\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Positional cloning of the pudgy mouse mutation revealed that Dll3 loss disrupts somite boundary formation and rostrocaudal patterning, establishing its non-redundant requirement in the Notch-dependent segmentation pathway.\",\n      \"evidence\": \"Positional cloning, complementation testing, and molecular marker analysis in pudgy mutant mice\",\n      \"pmids\": [\"9662403\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of DLL3 action in somitogenesis unclear\", \"Relationship to other Delta ligands not resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Human genetic studies linked loss-of-function DLL3 mutations to autosomal recessive spondylocostal dysostosis, confirming the conserved requirement for DLL3 in vertebral segmentation and pinpointing the EGF-like repeat domain as functionally critical.\",\n      \"evidence\": \"Sequencing of DLL3 in spondylocostal dysostosis families identifying truncating and missense mutations\",\n      \"pmids\": [\"10742114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical consequence of individual EGF-repeat mutations not tested\", \"No structure-function analysis\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Targeted Dll3 null alleles demonstrated that DLL3 is required for proper oscillatory expression of segmentation clock genes (Lfng, Hes1, Hes5, Hey1), placing DLL3 upstream of the oscillatory machinery rather than merely responding to it.\",\n      \"evidence\": \"Gene targeting (null allele) with in situ hybridization of cycling genes in mouse embryos\",\n      \"pmids\": [\"11923214\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DLL3 directly modulates the clock or acts indirectly through Notch signaling levels was unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Genetic epistasis between Dll1, Dll3, and Mesp2 revealed that these two Delta ligands have non-redundant, potentially counteracting roles in somite patterning, with Mesp2 acting downstream of both.\",\n      \"evidence\": \"Compound mutant mouse analysis with gene expression profiling\",\n      \"pmids\": [\"12900443\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for counteracting functions not identified\", \"Direct protein interactions not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The pivotal mechanistic question — whether DLL3 is a Notch activator or inhibitor — was resolved: DLL3 does not bind Notch in trans or activate signaling but instead cell-autonomously inhibits Notch in cis, explaining the paradoxical loss-of-function phenotype and redefining DLL3 as a dedicated cis-inhibitor.\",\n      \"evidence\": \"Multiple Notch activation, trans-binding, co-culture signaling, Xenopus neurogenesis, and neural progenitor differentiation assays\",\n      \"pmids\": [\"16144902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for inability to signal in trans unknown\", \"Mechanism of cis-inhibition at the molecular level unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The inability of DLL3 to activate Notch was traced to its lysine-free intracellular domain, which cannot mediate ubiquitin-dependent transendocytosis of the Notch extracellular domain — the mechanical step required for signal activation — even when the ectodomain is replaced with that of DLL1.\",\n      \"evidence\": \"Chimeric DLL1/DLL3 ligand construction with endocytosis, recycling, Notch1 binding, and transendocytosis assays in cell culture\",\n      \"pmids\": [\"18676613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional ectodomain features contribute to the lack of trans-signaling not fully excluded\", \"In vivo validation of chimera phenotype not performed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Three independent studies placed DLL3 within defined transcriptional and signaling networks: Ascl1/Neurog2 directly bind the Dll3 promoter to drive expression in neural tube; the Huwe1–N-Myc axis regulates DLL3 upstream to control neural stem cell expansion; and DLL3 is specifically required for Nrarp oscillation independently of Lfng.\",\n      \"evidence\": \"Transgenic reporters with E-box mutagenesis plus in vitro binding (Dll3 promoter); conditional Huwe1 KO with cortical neurogenesis phenotyping; Dll3/Lfng null expression analysis\",\n      \"pmids\": [\"19389376\", \"19686682\", \"19268448\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Ascl1-driven DLL3 expression is direct in presomitic mesoderm not tested\", \"Downstream effectors linking DLL3 cis-inhibition to Nrarp oscillation unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"O-fucosylation of DLL3 EGF repeats by POFUT1 was shown to be essential for in vivo somitogenesis function but dispensable for cis-inhibition in vitro, revealing a separable requirement for glycosylation during segmentation clock operation; DLL3 and LFNG physically interact in the trans-Golgi.\",\n      \"evidence\": \"Site-directed mutagenesis of O-fucosylation sites, transgenic rescue in Dll3 null embryos, co-immunoprecipitation, in vitro Notch inhibition assays\",\n      \"pmids\": [\"25856312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for why O-fucosylation is required in vivo but not in vitro unclear\", \"Structural details of DLL3-LFNG interaction not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"In SCLC, DLL3 was shown to have a tumor-promoting role: it drives migration and invasion through SNAI1 upregulation, and DLL3 mRNA is stabilized by LIN28B within a miR-518d-5p regulatory axis.\",\n      \"evidence\": \"siRNA/overexpression in SCLC lines with transwell assays and xenografts; RIP assay for LIN28B-DLL3 mRNA binding\",\n      \"pmids\": [\"30874360\", \"31079917\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking DLL3 to SNAI1 transcription not defined\", \"Whether DLL3's tumor role depends on cis-inhibition of Notch or an independent pathway is unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Compound Dll3/Lfng mutant analysis established that DLL3 and LFNG cooperate in the segmentation clock with DLL3 loss epistatic to LFNG loss, and that DLL3 in cells co-expressing DLL1 and NOTCH1 potentiates signal-sending activity in a glycosylation-modulated manner, providing an integrated model of oscillatory Notch regulation.\",\n      \"evidence\": \"Genetic epistasis (compound mutants), biochemical demonstration of LFNG modification of DLL3 EGF repeats, cell-based Notch signaling assays\",\n      \"pmids\": [\"35429490\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How cis-inhibition and signal-sending potentiation are balanced quantitatively during oscillation remains unresolved\", \"Direct visualization of DLL3 dynamics in the clock is lacking\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for DLL3's exclusive cis-inhibitory mode, the mechanism by which DLL3 upregulates SNAI1 in tumor cells, and whether DLL3's role in SCLC is Notch-dependent or involves Notch-independent signaling.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of DLL3 alone or in complex with Notch\", \"Molecular pathway connecting DLL3 to SNAI1 in SCLC undefined\", \"Whether DLL3 ubiquitination by MIB2 (observed in oocytes) is generalizable to other tissues is untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 8, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 8, 13]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3, 6, 8, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 2, 3, 4, 12, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LFNG\", \"DLL1\", \"NOTCH1\", \"ASCL1\", \"NEUROG2\", \"SNAI1\", \"LIN28B\", \"MESP2\"],\n    \"other_free_text\": []\n  }\n}\n```"}